TitleDate
SATELLOS BIOSCIENCE ANNOUNCES APPOINTMENT OF J. ROBERT HALL AS VICE-PRESIDENT, FINANCE AND ADMINISTRATIONSeptember 21, 2021
SATELLOS BIOSCIENCE Announces evidence for regeneration in severe model of DuchenneSeptember 13, 2021
SATELLOS BIOSCIENCE Announces Partnership with Jesse’s JourneySeptember 7, 2021
SATELLOS BIOSCIENCE Announces Second Quarter 2021 Financial Results and MD&ASeptember 1, 2021
SATELLOS BIOSCIENCE Announces High Resolution Crystal Structure of Duchenne Drug TargetAugust 27, 2021
SATELLOS BIOSCIENCE Announces Joint Development Agreement with NW PharmaTech Limited for Oral CBDAugust 18, 2021
Satellos and iCo Announce Completion of Reverse TakeoverAugust 13, 2021
iCo Therapeutics Inc. Announces Shareholder Approval of business combination with Satellos Bioscience Inc.August 5, 2021
iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update regarding Business Combination with Satellos Bioscience Inc.July 9, 2021
iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences MeetingMay 10, 2021
iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan KoppyMay 1, 2021
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private PlacementApril 28, 2021
iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private PlacementApril 23, 2021
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.March 22, 2021
iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2March 15, 2021
iCo Therapeutics Inc. Announces Warrant ExercisesMarch 11, 2021
iCo Therapeutics Inc. Proposes to Re-Price WarrantsJanuary 11, 2021
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount MedicalDecember 31, 2020
iCo Therapeutics Announces Third Quarter 2020 Financial ResultsNovember 24, 2020
iCo Therapeutics Announces Option GrantsOctober 26, 2020
iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020October 21, 2020
iCo Therapeutics Announces Second Quarter 2020 Financial ResultsAugust 31, 2020
iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases JournalJuly 30, 2020